Sundry Photography/iStock Editorial via Getty Images
- Swiss biopharma Addex Therapeutics (NASDAQ:ADXN) announced Thursday that Johnson & Johnson (NYSE:JNJ) has returned all development and commercialization rights linked to its epilepsy candidate ADX71149, ending a more than 20-year-long partnership between the two firms.
- J&Jās decision comes nearly nine